Rocket Lab Corp director Merline Saintil executed two planned sales transactions on June 24, 2025, disposing of a total of 6,353 shares of common stock through a pre-established Rule 10b5-1 trading plan from March 20, 2025.
Transaction details:
- First sale: 4,053 shares at weighted average price of $33.1473 (range: $32.51-$33.50)
- Second sale: 2,300 shares at weighted average price of $33.7848 (range: $33.51-$34.13)
- Remaining direct ownership: 419,569 shares
The transactions were executed according to a predetermined trading plan, which provides an affirmative defense against insider trading allegations. The sales were reported within the required two-business-day filing deadline.
Rocket Lab Corp (RKLB) director Merline Saintil executed planned stock sales on June 20, 2025, through a pre-established Rule 10b5-1 trading plan from March 20, 2025. The transactions involved:
- Sale of 1,700 shares at a weighted average price of $28.75 (range: $28.03-$29.01)
- Sale of 4,653 shares at a weighted average price of $29.65 (range: $29.08-$30.04)
Following these transactions, Saintil's direct ownership decreased from 432,275 to 425,922 shares. The sales were executed automatically according to the trading plan, demonstrating structured portfolio management by the insider. The Form 4 was signed by Arjun Kampani as Attorney-in-Fact for Saintil on June 23, 2025.
Rocket Lab Corporation (NASDAQ: RKLB) has filed a Form 144 notice indicating a proposed sale of securities by an insider. The filing details plans to sell 12,706 shares of common stock with an aggregate market value of $353,862.10, representing a small portion of the company's 461,432,393 outstanding shares.
Key transaction details:
- Shares were acquired through Restricted Stock Units on June 12, 2025
- Sale to be executed through Morgan Stanley Smith Barney LLC
- Approximate sale date: June 20, 2025
- Average price per share: approximately $27.85
The filing indicates no other sales by the insider in the past three months. The seller has certified compliance with Rule 10b5-1 and confirms no knowledge of undisclosed material adverse information regarding Rocket Lab's operations.